ADC Could Benefit Some with Breast Cancer
- PMID: 30867160
- DOI: 10.1158/2159-8290.CD-NB2019-034
ADC Could Benefit Some with Breast Cancer
Abstract
Results from a phase I/II trial suggest that an antibody-drug conjugate, sacituzumab govitecan, is active against refractory, metastatic triple-negative breast cancer. A phase III trial is under way to compare its safety and efficacy with that of standard chemotherapy.
©2019 American Association for Cancer Research.
Comment on
-
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213. N Engl J Med. 2019. PMID: 30786188 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources